MARKET

PROK

PROK

ProKidney
NASDAQ
1.640
-0.020
-1.20%
Pre Market: 1.640 0 0.00% 04:00 06/15 EDT
OPEN
1.650
PREV CLOSE
1.660
HIGH
1.715
LOW
1.610
VOLUME
861
TURNOVER
0
52 WEEK HIGH
7.13
52 WEEK LOW
0.5400
MARKET CAP
495.38M
P/E (TTM)
-3.1167
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PROK last week (0601-0605)?
Weekly Report · 6d ago
ProKidney appoints Kenneth Locke as chief technical officer
TipRanks · 06/02 13:29
ProKidney names Kenneth Locke chief technical officer
PUBT · 06/02 12:06
PROKIDNEY APPOINTS KENNETH LOCKE AS CHIEF TECHNICAL OFFICER
Reuters · 06/02 12:00
Press Release: ProKidney Appoints Kenneth Locke as Chief Technical Officer
Dow Jones · 06/02 12:00
Weekly Report: what happened at PROK last week (0525-0529)?
Weekly Report · 06/01 10:38
ProKidney shareholders reaffirm board and auditor at 2026 meeting
TipRanks · 05/29 21:12
Weekly Report: what happened at PROK last week (0518-0522)?
Weekly Report · 05/25 10:42
More
About PROK
Prokidney Corp. is a late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD). The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD.

Webull offers ProKidney Corp stock information, including NASDAQ: PROK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PROK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PROK stock methods without spending real money on the virtual paper trading platform.